Spectrum Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SPPI)

$20.30 -0.86 (-4.06 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$20.30
Today's Range$20.25 - $21.15
52-Week Range$5.47 - $23.50
Volume792,500 shs
Average Volume965,950 shs
Market Capitalization$2.13 billion
P/E Ratio-20.50
Dividend YieldN/A
Beta1.64

About Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals logoSpectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

Receive SPPI News and Ratings via Email

Sign-up to receive the latest news and ratings for SPPI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300

Debt

Debt-to-Equity Ratio0.33%
Current Ratio5.04%
Quick Ratio4.89%

Price-To-Earnings

Trailing P/E Ratio-20.5048433854204
Forward P/E Ratio-20.71
P/E GrowthN/A

Sales & Book Value

Annual Sales$146.44 million
Price / Sales13.95
Cash FlowN/A
Price / CashN/A
Book Value$2.93 per share
Price / Book6.93

Profitability

Trailing EPS($0.99)
Net Income$-68,510,000.00
Net Margins-58.94%
Return on Equity-29.73%
Return on Assets-16.45%

Miscellaneous

Employees227
Outstanding Shares100,660,000

Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions

What is Spectrum Pharmaceuticals' stock symbol?

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

How were Spectrum Pharmaceuticals' earnings last quarter?

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings results on Thursday, November, 2nd. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.06. The biotechnology company earned $36.40 million during the quarter, compared to the consensus estimate of $33.27 million. Spectrum Pharmaceuticals had a negative net margin of 58.94% and a negative return on equity of 29.73%. The business's quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.07) earnings per share. View Spectrum Pharmaceuticals' Earnings History.

Where is Spectrum Pharmaceuticals' stock going? Where will Spectrum Pharmaceuticals' stock price be in 2018?

5 equities research analysts have issued 12 month price objectives for Spectrum Pharmaceuticals' shares. Their predictions range from $11.00 to $33.00. On average, they anticipate Spectrum Pharmaceuticals' share price to reach $25.40 in the next year. View Analyst Ratings for Spectrum Pharmaceuticals.

Who are some of Spectrum Pharmaceuticals' key competitors?

Who are Spectrum Pharmaceuticals' key executives?

Spectrum Pharmaceuticals' management team includes the folowing people:

  • Stuart Mitchell Krassner, Chairman of the Board (Age 81)
  • Joseph W. Turgeon, President, Chief Executive Officer, Director (Age 59)
  • Kurt A. Gustafson, Chief Financial Officer, Executive Vice President (Age 49)
  • Thomas J. Riga, Chief Operating Officer
  • Luigi Lenaz M.D., Lead Independent Director (Age 76)
  • Gilles R. Gagnon, Director (Age 63)
  • Raymond Wayne Cohen, Independent Director (Age 58)
  • Anthony E. Maida III, Ph.D., Independent Director (Age 65)
  • Dolatrai Vyas Ph.D., Independent Director (Age 73)

Who owns Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.89%), Consonance Capital Management LP (7.34%), Renaissance Technologies LLC (6.14%), Goldman Sachs Group Inc. (1.85%), Bank of New York Mellon Corp (1.04%) and Wells Fargo & Company MN (0.97%). View Institutional Ownership Trends for Spectrum Pharmaceuticals.

Who sold Spectrum Pharmaceuticals stock? Who is selling Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, Macquarie Group Ltd., Deutsche Bank AG, Renaissance Technologies LLC, Teachers Advisors LLC, Two Sigma Investments LP, Kennedy Capital Management Inc. and Two Sigma Advisers LP. View Insider Buying and Selling for Spectrum Pharmaceuticals.

Who bought Spectrum Pharmaceuticals stock? Who is buying Spectrum Pharmaceuticals stock?

Spectrum Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bogle Investment Management L P DE, Ashford Capital Management Inc., TIAA CREF Investment Management LLC, Geode Capital Management LLC, Candriam Luxembourg S.C.A., Guggenheim Capital LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Spectrum Pharmaceuticals.

How do I buy Spectrum Pharmaceuticals stock?

Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spectrum Pharmaceuticals' stock price today?

One share of Spectrum Pharmaceuticals stock can currently be purchased for approximately $20.30.

How big of a company is Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals has a market capitalization of $2.13 billion and generates $146.44 million in revenue each year. The biotechnology company earns $-68,510,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Spectrum Pharmaceuticals employs 227 workers across the globe.

How can I contact Spectrum Pharmaceuticals?

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]


MarketBeat Community Rating for Spectrum Pharmaceuticals (SPPI)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spectrum Pharmaceuticals (NASDAQ:SPPI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $25.40$24.60$24.25$11.00
Price Target Upside: 15.45% upside29.20% upside26.11% upside17.52% upside

Spectrum Pharmaceuticals (NASDAQ:SPPI) Consensus Price Target History

Price Target History for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ:SPPI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/5/2018HC WainwrightBoost Price TargetPositive -> Buy$33.00HighView Rating Details
12/18/2017B. RileyInitiated CoverageBuy -> Buy$26.00HighView Rating Details
10/23/2017GuggenheimInitiated CoverageBuy$32.00N/AView Rating Details
10/20/2017Jefferies GroupBoost Price TargetBuy$25.00N/AView Rating Details
4/1/2017FBR & CoReiterated RatingBuyMediumView Rating Details
9/15/2016Royal Bank of CanadaSet Price TargetBuy$11.00 -> $10.00N/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings History and Estimates Chart

Earnings by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ SPPI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.16)($0.22)$33.27 million$36.40 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.27)($0.26)$30.50 million$34.30 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.20)($0.18)$32.23 million$29.10 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.27)($0.22)$31.13 million$35.24 millionViewListenView Earnings Details
11/14/2016Q3 2016($0.30)($0.22)$29.53 million$33.39 millionViewN/AView Earnings Details
8/9/2016Q216($0.29)($0.05)$30.88 million$33.90 millionViewN/AView Earnings Details
5/5/2016Q1($0.32)($0.14)$28.83 million$43.90 millionViewN/AView Earnings Details
3/9/2016Q415($0.18)($0.06)$33.87 million$50.30 millionViewN/AView Earnings Details
11/4/2015Q315($0.25)($0.28)$31.87 million$28.46 millionViewN/AView Earnings Details
8/6/2015Q215($0.22)($0.01)$34.48 million$44.98 millionViewN/AView Earnings Details
5/7/2015Q115($0.06)($0.07)$48.00 million$38.60 millionViewN/AView Earnings Details
3/13/2015Q414($0.16)$0.09$48.50 million$51.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.17)$0.08$45.00 million$47.99 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)$0.09$41.50 million$46.90 millionViewListenView Earnings Details
5/8/2014Q114($0.22)$0.01$39.49 million$40.10 millionViewListenView Earnings Details
3/6/2014Q313($0.11)$0.05$41.96 million$41.50 millionViewListenView Earnings Details
11/12/2013Q3($0.07)($0.13)$38.70 million$42.44 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.12)($0.08)$33.41 million$33.23 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.32)($0.06)$49.88 million$38.67 millionViewN/AView Earnings Details
2/21/2013Q4 2012$0.16$0.18ViewN/AView Earnings Details
11/7/2012Q312$0.29$0.42$68.56 million$69.00 millionViewN/AView Earnings Details
8/8/2012Q2 2012$0.31$0.34ViewN/AView Earnings Details
4/26/2012Q1 2012$0.28$0.35ViewN/AView Earnings Details
3/1/2012Q4 2011$0.28$0.13ViewN/AView Earnings Details
10/28/2011Q3 2011$0.09$0.29ViewN/AView Earnings Details
8/4/2011Q2 2011$0.13$0.13ViewN/AView Earnings Details
5/4/2011Q1 2011$0.01$0.33ViewN/AView Earnings Details
3/10/2011Q4 2010($0.04)$0.14ViewN/AView Earnings Details
11/4/2010Q3 2010($0.22)($0.07)ViewN/AView Earnings Details
8/9/2010Q2 2010($0.15)($0.20)ViewN/AView Earnings Details
5/10/2010Q1 2010($0.15)($0.78)ViewN/AView Earnings Details
4/5/2010Q4 2009($0.20)($0.19)ViewN/AView Earnings Details
11/12/2009Q3 2009($0.20)($0.17)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.14)($0.28)ViewN/AView Earnings Details
5/18/2009Q1 2009($0.11)$0.02ViewN/AView Earnings Details
3/31/2009Q4 2008($0.17)($0.12)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.32)($0.28)ViewN/AView Earnings Details
8/12/2008Q2 2008($0.34)$0.34ViewN/AView Earnings Details
5/13/2008Q1 2008($0.40)($0.28)ViewN/AView Earnings Details
3/14/2008Q4 2007($0.38)($0.41)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Spectrum Pharmaceuticals (NASDAQ:SPPI) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.98 EPS
Next Year EPS Consensus Estimate: $-0.89 EPS

Dividends

Spectrum Pharmaceuticals (NASDAQ:SPPI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/11/2012special$0.1512/18/201212/20/201212/28/2012
(Data available from 1/1/2013 forward)

Insider Trades

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.33%
Institutional Ownership Percentage: 79.96%
Insider Trades by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)
Institutional Ownership by Quarter for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/5/2013Anthony E Maida IIIDirectorSell5,000$12.25$61,250.00View SEC Filing  
11/12/2012Joseph Kenneth KellerCOOBuy10,000$10.95$109,500.00View SEC Filing  
11/1/2012Anthony E Maida IIIDirectorSell5,000$11.09$55,450.00View SEC Filing  
9/4/2012Anthony E Maida IIIDirectorSell5,000$12.01$60,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spectrum Pharmaceuticals (NASDAQ SPPI) News Headlines

Source:
DateHeadline
Spectrum Pharmaceuticals to Present Corporate Update at the 2018 RBC Capital Markets Global Healthcare Conference on February 22ndSpectrum Pharmaceuticals to Present Corporate Update at the 2018 RBC Capital Markets Global Healthcare Conference on February 22nd
finance.yahoo.com - February 15 at 9:44 AM
Jefferies Group Comments on Spectrum Pharmaceuticals, Inc.s FY2017 Earnings (SPPI)Jefferies Group Comments on Spectrum Pharmaceuticals, Inc.'s FY2017 Earnings (SPPI)
www.americanbankingnews.com - February 15 at 7:56 AM
Jefferies Group Research Analysts Decrease Earnings Estimates for Spectrum Pharmaceuticals, Inc. (SPPI)Jefferies Group Research Analysts Decrease Earnings Estimates for Spectrum Pharmaceuticals, Inc. (SPPI)
www.americanbankingnews.com - February 14 at 3:52 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Post Quarterly Sales of $34.00 MillionSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Post Quarterly Sales of $34.00 Million
www.americanbankingnews.com - February 12 at 10:44 AM
[$$] Buying United, Selling Lilly, Rambus, Tronc[$$] Buying United, Selling Lilly, Rambus, Tronc
finance.yahoo.com - February 12 at 9:33 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by BrokeragesSpectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 10 at 5:34 PM
Wired News – Spectrum Pharma’s ROLONTIS Achieved Primary Endpoint in Phase-3 ADVANCE StudyWired News – Spectrum Pharma’s ROLONTIS Achieved Primary Endpoint in Phase-3 ADVANCE Study
finance.yahoo.com - February 7 at 9:25 AM
Spectrum Pharmas Rolontis Positive in Pivotal Cancer StudySpectrum Pharma's Rolontis Positive in Pivotal Cancer Study
finance.yahoo.com - February 6 at 3:41 PM
Bristol-Myers Squibb, Spectrum Just Reported Key Late Stage DataBristol-Myers Squibb, Spectrum Just Reported Key Late Stage Data
finance.yahoo.com - February 6 at 9:16 AM
Spectrum Pharma (SPPI) Reports ROLONTIS (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE StudySpectrum Pharma (SPPI) Reports ROLONTIS (eflapegrastim) Met the Primary Endpoint in the Phase 3 ADVANCE Study
www.streetinsider.com - February 5 at 3:39 PM
HC Wainwright Boosts Spectrum Pharmaceuticals (SPPI) Price Target to $33.00HC Wainwright Boosts Spectrum Pharmaceuticals (SPPI) Price Target to $33.00
www.americanbankingnews.com - February 5 at 9:40 AM
Spectrum Pharmaceuticals (SPPI) Downgraded by BidaskClubSpectrum Pharmaceuticals (SPPI) Downgraded by BidaskClub
www.americanbankingnews.com - February 3 at 2:32 PM
Spectrum Pharmaceuticals (SPPI) Stock Rating Upgraded by BidaskClubSpectrum Pharmaceuticals (SPPI) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - January 27 at 12:18 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $34.00 MillionSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $34.00 Million
www.americanbankingnews.com - January 26 at 6:48 AM
Investors Purchase High Volume of Put Options on Spectrum Pharmaceuticals (SPPI)Investors Purchase High Volume of Put Options on Spectrum Pharmaceuticals (SPPI)
www.americanbankingnews.com - January 26 at 2:24 AM
Investors Purchase High Volume of Spectrum Pharmaceuticals Call Options (SPPI)Investors Purchase High Volume of Spectrum Pharmaceuticals Call Options (SPPI)
www.americanbankingnews.com - January 25 at 2:34 AM
Spectrum Pharmaceuticals Inc’s (NASDAQ:SPPI) Earnings Dropped -44.12%, Did Its Industry Show Weakness Too?Spectrum Pharmaceuticals Inc’s (NASDAQ:SPPI) Earnings Dropped -44.12%, Did Its Industry Show Weakness Too?
finance.yahoo.com - January 23 at 5:27 PM
Spectrum Pharmaceuticals Up 134% in 6 Months: Heres Why - NasdaqSpectrum Pharmaceuticals Up 134% in 6 Months: Here's Why - Nasdaq
www.nasdaq.com - January 20 at 7:36 AM
Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS - PR Newswire (press release)Free Research Reports on These Biotech Stocks -- Spectrum Pharma, Teligent, Vertex Pharma, and VIVUS - PR Newswire (press release)
www.prnewswire.com - January 17 at 3:24 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Receives Average Recommendation of "Buy" from BrokeragesSpectrum Pharmaceuticals, Inc. (SPPI) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 16 at 5:34 PM
Spectrum Pharmaceuticals (SPPI) Raised to "Hold" at Zacks Investment ResearchSpectrum Pharmaceuticals (SPPI) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 12 at 9:38 PM
$33.05 Million in Sales Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter$33.05 Million in Sales Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter
www.americanbankingnews.com - January 9 at 3:02 PM
Spectrum Pharmaceuticals (SPPI) Downgraded by Zacks Investment ResearchSpectrum Pharmaceuticals (SPPI) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 2 at 12:00 PM
Spectrum Pharmaceuticals: Buy The Dip - Seeking AlphaSpectrum Pharmaceuticals: Buy The Dip - Seeking Alpha
seekingalpha.com - December 24 at 3:34 PM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $33.05 MillionSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Quarterly Sales of $33.05 Million
www.americanbankingnews.com - December 23 at 5:00 AM
Stock Traders Buy Large Volume of Spectrum Pharmaceuticals Put Options (SPPI)Stock Traders Buy Large Volume of Spectrum Pharmaceuticals Put Options (SPPI)
www.americanbankingnews.com - December 23 at 2:52 AM
 Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Earnings of -$0.25 Per Share Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - December 21 at 5:10 PM
Spectrum Pharmaceuticals Inc (NASDAQ:SPPI): What Does The Future Look Like?Spectrum Pharmaceuticals Inc (NASDAQ:SPPI): What Does The Future Look Like?
finance.yahoo.com - December 21 at 7:57 AM
Spectrum Pharmaceuticals IncSpectrum Pharmaceuticals Inc
www.bloomberg.com - December 20 at 3:23 PM
B. Riley Initiates Coverage on Spectrum Pharmaceuticals (SPPI)B. Riley Initiates Coverage on Spectrum Pharmaceuticals (SPPI)
www.americanbankingnews.com - December 18 at 9:52 PM
Spectrum Pharma Dismisses CEO, Makes Leadership Changes ... - NasdaqSpectrum Pharma Dismisses CEO, Makes Leadership Changes ... - Nasdaq
www.nasdaq.com - December 18 at 3:23 PM
Spectrum Pharmaceuticals (SPPI) "Buy" Rating Reaffirmed at HC WainwrightSpectrum Pharmaceuticals' (SPPI) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - December 18 at 1:36 PM
Spectrum Pharmaceuticals Announces Leadership Changes - Business Wire (press release)Spectrum Pharmaceuticals Announces Leadership Changes - Business Wire (press release)
www.businesswire.com - December 18 at 7:35 AM
Pre-Market Technical Scan on Biotech Equities -- Spectrum Pharma, Jazz Pharma, Intra-Cellular Therapies, and Dermira - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- Spectrum Pharma, Jazz Pharma, Intra-Cellular Therapies, and Dermira - PR Newswire (press release)
www.prnewswire.com - December 13 at 7:53 AM
Spectrum Pharma (SPPI) Announces Two Oral Presentations on FOLOTYN (Pralatrexate Injection) - StreetInsider.comSpectrum Pharma (SPPI) Announces Two Oral Presentations on FOLOTYN (Pralatrexate Injection) - StreetInsider.com
www.streetinsider.com - December 13 at 7:53 AM
Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)
finance.yahoo.com - December 13 at 7:53 AM
An Overview of Spectrum Pharmaceuticals’ Drug PipelineAn Overview of Spectrum Pharmaceuticals’ Drug Pipeline
finance.yahoo.com - December 12 at 3:23 PM
A Look at Spectrum Pharmaceuticals’ Recent AcquisitionsA Look at Spectrum Pharmaceuticals’ Recent Acquisitions
finance.yahoo.com - December 12 at 7:49 AM
Spectrum Pharmaceuticals’ Product Licensing AgreementsSpectrum Pharmaceuticals’ Product Licensing Agreements
finance.yahoo.com - December 12 at 7:49 AM
Stock Traders Purchase Large Volume of Spectrum Pharmaceuticals Call Options (SPPI)Stock Traders Purchase Large Volume of Spectrum Pharmaceuticals Call Options (SPPI)
www.americanbankingnews.com - December 8 at 1:32 AM
18 small-cap stocks that analysts expect to rise at least 50% in 201818 small-cap stocks that analysts expect to rise at least 50% in 2018
finance.yahoo.com - December 6 at 8:12 AM
Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology ... - Business Wire (press release)Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology ... - Business Wire (press release)
www.businesswire.com - December 4 at 7:41 AM
Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017Spectrum Pharmaceuticals Highlights 15 Abstracts at the 59th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia, December 9-12, 2017
finance.yahoo.com - December 4 at 7:41 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by AnalystsSpectrum Pharmaceuticals, Inc. (SPPI) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 27 at 5:50 PM
Spectrum Doubles in 3 Months: Whats Driving the Rally?Spectrum Doubles in 3 Months: What's Driving the Rally?
finance.yahoo.com - November 27 at 4:11 PM
Financial Survey: Spectrum Pharmaceuticals (SPPI) versus Its CompetitorsFinancial Survey: Spectrum Pharmaceuticals (SPPI) versus Its Competitors
www.americanbankingnews.com - November 20 at 1:30 AM
Today’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Myriad GeneticsToday’s Research Reports on Trending Tickers: Spectrum Pharmaceuticals and Myriad Genetics
finance.yahoo.com - November 18 at 8:57 AM
Spectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Earnings of -$0.25 Per ShareSpectrum Pharmaceuticals, Inc. (SPPI) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - November 15 at 11:41 AM
Why Spectrum Pharmaceuticals Stock Soared in OctoberWhy Spectrum Pharmaceuticals Stock Soared in October
www.fool.com - November 8 at 12:19 PM
Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates - NasdaqSpectrum (SPPI) Earnings, Sales Beat Q3 Estimates - Nasdaq
www.nasdaq.com - November 5 at 2:41 AM

SEC Filings

Spectrum Pharmaceuticals (NASDAQ:SPPI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Spectrum Pharmaceuticals (NASDAQ:SPPI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spectrum Pharmaceuticals (NASDAQ SPPI) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.